Zkusit zdarma
Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

NBIX
Cena:
$ 156.70
+1.20 (0.77%)
Valuace
48
Růst
100
Zdraví
61
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

16:05 18-05-2026

Clinician survey showed 90% of patients with mild tardive dyskinesia experienced emotional, social o...

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

8:46 18-05-2026

Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatm...

Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

19:50 12-05-2026

Neurocrine Biosciences, Inc. (NBIX) Presents at Bank of America Global Healthcare Conference 2026 Tr...

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why

13:45 07-05-2026

Neurocrine (NBIX) is well positioned to outperform the market, as it exhibits above-average growth i...

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia

8:30 06-05-2026

New algorithms developed by expert clinical endocrinologists provide clear, practical recommendation...

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript

22:31 05-05-2026

Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript...

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

18:30 05-05-2026

While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business perfor...

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

18:16 05-05-2026

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.94 per share, beating the Zacks...

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

16:01 05-05-2026

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Anno...

Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026

9:00 05-05-2026

SAN DIEGO, May 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today t...

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment

8:30 04-05-2026

Approximately 1 in 5 surveyed working adults with tardive dyskinesia reported quitting their job due...

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist

7:30 04-05-2026

NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation SAN DIE...

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia

16:05 01-05-2026

At two years, 60% of patients who were overweight or obese at baseline experienced clinically meanin...

Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

16:05 29-04-2026

Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement ...

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

11:06 28-04-2026

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earn...

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia

16:05 22-04-2026

Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑ran...

3 Reasons Growth Investors Will Love Neurocrine (NBIX)

3 Reasons Growth Investors Will Love Neurocrine (NBIX)

13:46 21-04-2026

Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the mark...

Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet

Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet

10:57 21-04-2026

The consensus price target hints at a 38.8% upside potential for Neurocrine (NBIX). While empirical ...

Fortis Capital Advisors LLC Invests $1.35 Million in Neurocrine Biosciences, Inc. $NBIX

Fortis Capital Advisors LLC Invests $1.35 Million in Neurocrine Biosciences, Inc. $NBIX

4:16 20-04-2026

Fortis Capital Advisors LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:...

Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock?

Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock?

15:36 15-04-2026

Investors need to pay close attention to NBIX stock based on the movements in the options market lat...

close

NEUROCRINE BIOSCIENCES REPORTS FOURTH-QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES FINANCIAL EXPECTATIONS FOR 2026

11-02-2026
TOTAL FOURTH-QUARTER AND FULL-YEAR 2025 NET PRODUCT SALES OF $798.3 MILLION AND $2.83 BILLION, REPRE...
Více zde

NEUROCRINE BIOSCIENCES INITIATES PHASE 2 CLINICAL STUDY EVALUATING NBI-1065890 IN ADULTS WITH TARDIVE DYSKINESIA

26-01-2026
SAN DIEGO, JAN. 26, 2026 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUNCED...
Více zde

NEUROCRINE BIOSCIENCES ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND YEAR-END 2025 FINANCIAL RESULTS

21-01-2026
CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, FEBRUARY 11 SAN DIEGO, JAN. 21, 2026 /PRNEWSWIR...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS HEAD-TO-HEAD INGREZZA® (VALBENAZINE) CAPSULES DATA DEMONSTRATING HIGHER VMAT2 TARGET OCCUPANCY COMPARED TO AUSTEDO XR

15-01-2026
INGREZZA SHOWED A NEARLY TWO-FOLD HIGHER VMAT2 OCCUPANCY, CONSISTENT WITH GREATER POTENCY WHEN COMPA...
Více zde

NEUROCRINE BIOSCIENCES TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

05-01-2026
SAN DIEGO, JAN. 5, 2026 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) WILL PRESENT AT ...
Více zde

NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON PHASE 3 STUDY OF VALBENAZINE IN DYSKINETIC CEREBRAL PALSY

22-12-2025
SAN DIEGO , DEC. 22, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUN...
Více zde

NEUROCRINE BIOSCIENCES SHOWCASES R&D TRANSFORMATION DRIVING INNOVATION ACROSS NEUROSCIENCE AND ENDOCRINOLOGY

16-12-2025
PROVIDED UPDATE ON R&D ENGINE NOW ON TRACK TO DELIVER MULTIPLE FIRST- AND BEST-IN-CLASS MEDICINES, P...
Více zde

NEUROCRINE BIOSCIENCES TO HOST R&D DAY ON DECEMBER 16

09-12-2025
SAN DIEGO , DEC. 9, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUNCED...
Více zde

NEUROCRINE BIOSCIENCES ANNOUNCES PUBLICATION OF LANDMARK NARRATIVE REVIEW ON FDA-APPROVED VMAT2 INHIBITORS DEMONSTRATING UNIQUE PROFILE OF INGREZZA® (VALBENAZINE) CAPSULES

20-11-2025
PUBLISHED, PEER-REVIEWED NARRATIVE REVIEW IN CNS SPECTRUMS COMPILES PHARMACOLOGIC, PHARMACOKINETIC A...
Více zde

NEUROCRINE BIOSCIENCES TO PRESENT AT UPCOMING INVESTOR CONFERENCES

11-11-2025
SAN DIEGO , NOV. 11, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUNCE...
Více zde

NEUROCRINE BIOSCIENCES PROVIDES UPDATE ON PHASE 2 STUDY OF NBI-1070770 IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

10-11-2025
SAN DIEGO , NOV. 10, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUNCE...
Více zde

NEUROCRINE BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

28-10-2025
ACHIEVED TOTAL NET PRODUCT SALES OF $790 MILLION REPRESENTING 28% YEAR-OVER-YEAR GROWTH INGREZZA® (...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS NEW KINECT® 4 POST-HOC ANALYSIS DEMONSTRATING RAPID AND SUSTAINED THERAPEUTIC EFFICACY OF INGREZZA® (VALBENAZINE) 40 MG CAPSULES

17-10-2025
CONTINUOUS TREATMENT WITH INGREZZA 40 MG FOR 48 WEEKS RESULTED IN SUSTAINED, CLINICALLY MEANINGFUL ...
Více zde

NEUROCRINE BIOSCIENCES ANNOUNCES CONFERENCE CALL AND WEBCAST OF THIRD QUARTER 2025 FINANCIAL RESULTS

07-10-2025
CONFERENCE CALL AND WEBCAST SCHEDULED FOR TUESDAY, OCTOBER 28 SAN DIEGO , OCT. 7, 2025 /PRNEWSWIRE/ ...
Více zde

NEUROCRINE BIOSCIENCES APPOINTS MIKE SIBLEY AS SENIOR VICE PRESIDENT, GENERAL MANAGER OF NEUROPSYCHIATRY FRANCHISE

06-10-2025
SAN DIEGO , OCT. 6, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUNCED...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS NEW THREE-YEAR DATA DEMONSTRATING SUSTAINED CLINICAL BENEFITS AND ESTABLISHED SAFETY PROFILE OF INGREZZA® (VALBENAZINE) CAPSULES FOR HUNTINGTON'S DISEASE CHOREA

06-10-2025
ONCE-DAILY INGREZZA TREATMENT WAS GENERALLY WELL TOLERATED AND SHOWED EARLY AND SUSTAINED IMPROVEMEN...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS NEW POST-HOC ANALYSIS: TREATMENT WITH INGREZZA® (VALBENAZINE) CAPSULES ACHIEVES EARLIER REMISSION OF TARDIVE DYSKINESIA SYMPTOMS WHILE REDUCING PATIENT-REPORTED DISEASE BURDEN

23-09-2025
THE KINECT-PRO™ ANALYSIS IS THE FIRST AND ONLY OF ITS KIND TO REPORT BOTH REMISSION OF TARDIVE DYS...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS POSITIVE NEW DATA FROM PHASE 2 STUDY OF OSAVAMPATOR IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

22-09-2025
SAN DIEGO , SEPT. 22, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOU...
Více zde

NEUROCRINE BIOSCIENCES TO PRESENT NEW DATA FROM PHASE 2 STUDY OF OSAVAMPATOR IN ADULTS WITH MAJOR DEPRESSIVE DISORDER AT 38TH ANNUAL PSYCH CONGRESS 2025

16-09-2025
ADDITIONAL DATA FROM SAVITRI™ STUDY EXPAND ON TOP-LINE RESULTS ANNOUNCED IN APRIL 2024 SAVITRI POS...
Více zde

NEUROCRINE BIOSCIENCES TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN SEPTEMBER

26-08-2025
SAN DIEGO , AUG. 26, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) WILL PARTICIPA...
Více zde

NEUROCRINE BIOSCIENCES TO PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

06-08-2025
SAN DIEGO , AUG. 6, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) WILL PARTICIPAT...
Více zde

NEUROCRINE BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

30-07-2025
ACHIEVED TOTAL NET PRODUCT SALES OF $682 MILLION REPRESENTING 17% YEAR-OVER-YEAR GROWTH INGREZZA® (...
Více zde

NEUROCRINE BIOSCIENCES LEVERAGES PICNICHEALTH TO REVEAL CRITICAL CARE GAPS FOR PATIENTS WITH RARE GENETIC CONDITION

15-07-2025
TECHNOLOGY-ENABLED RESEARCH APPROACH AND AI-POWERED ANALYSIS IDENTIFY UNMET NEEDS IN PATIENTS WITH C...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS NEW ANALYSIS OF CAHTALOG® REGISTRY SHOWING MOST PATIENTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA EXPERIENCED HIGH GLUCOCORTICOID EXPOSURE, SUBOPTIMAL DISEASE CONTROL OR BOTH AT ENDO 2025

15-07-2025
APPROXIMATELY 95% OF ADULT AND PEDIATRIC PATIENTS WERE EXPOSED TO SUPRAPHYSIOLOGIC DOSES OF GLUCOCOR...
Více zde

NEUROCRINE BIOSCIENCES PRESENTED ONE-YEAR DATA FROM PHASE 3 CAHTALYST™ STUDIES SHOWING IMPROVEMENTS IN WEIGHT-RELATED EFFECTS OF GLUCOCORTICOID TREATMENT AT THE 2025 ENDOCRINE SOCIETY'S ANNUAL MEETING

14-07-2025
ADULT AND PEDIATRIC PATIENTS WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA TREATED WITH CRENESSITY® (...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS ONE-YEAR DATA SHOWING SUSTAINED EFFICACY OF CRENESSITY® (CRINECERFONT) IN ADULT PATIENTS, AT ENDO 2025

14-07-2025
ONE-YEAR DATA FROM CAHTALYST™ ADULT STUDY DEMONSTRATED LASTING REDUCTIONS IN GLUCOCORTICOID DOSE ...
Více zde

NEUROCRINE BIOSCIENCES ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER 2025 FINANCIAL RESULTS

09-07-2025
CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, JULY 30 SAN DIEGO , JULY 9, 2025 /PRNEWSWIRE/ -...
Více zde

NEUROCRINE BIOSCIENCES ANNOUNCES INITIATION OF PHASE 1 CLINICAL STUDY EVALUATING NBIP-01435, A LONG-ACTING CORTICOTROPIN-RELEASING FACTOR TYPE 1 RECEPTOR ANTAGONIST

30-06-2025
SAN DIEGO , JUNE 30, 2025 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUNC...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS NEW POST-HOC DATA ANALYSES FROM KINECT®-HD STUDY DEMONSTRATING SIGNIFICANT REDUCTION IN DISEASE BURDEN WITH INGREZZA® (VALBENAZINE) CAPSULES FOR HUNTINGTON'S DISEASE CHOREA

27-06-2025
PATIENT-REPORTED ANALYSES DEMONSTRATED GREATER REDUCTION IN BOTH COGNITIVE AND MOTOR-RELATED DISEASE...
Více zde

NEUROCRINE BIOSCIENCES PRESENTS NEW DATA SHOWING SIGNIFICANT PATIENT-REPORTED IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE WITH INGREZZA® (VALBENAZINE) CAPSULES IN OLDER ADULTS WITH TARDIVE DYSKINESIA

20-06-2025
DATA ADD TO GROWING BODY OF EVIDENCE DEMONSTRATING FUNCTIONAL AND QUALITY OF LIFE IMPROVEMENTS IN PA...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-11 00:00:008-KStáhnout
2026-02-11 00:00:0010-KStáhnout
2025-11-24 00:00:008-KStáhnout
2025-10-28 00:00:008-KStáhnout
2025-10-28 00:00:0010-QStáhnout
2025-07-30 01:00:008-KStáhnout
2025-07-30 01:00:0010-QStáhnout
2025-07-30 00:00:008-KStáhnout
2025-07-30 00:00:0010-QStáhnout
2025-05-30 01:00:008-KStáhnout
2025-05-30 00:00:008-KStáhnout
2025-05-22 01:00:008-KStáhnout
2025-05-22 00:00:008-KStáhnout
2025-05-05 01:00:008-KStáhnout
2025-05-05 01:00:0010-QStáhnout
2025-05-05 00:00:008-KStáhnout
2025-05-05 00:00:0010-QStáhnout
2025-04-04 01:00:008-KStáhnout
2025-04-04 00:00:008-KStáhnout
2025-02-10 00:00:0010-KStáhnout
2025-02-09 23:00:0010-KStáhnout
2025-02-06 00:00:008-KStáhnout
2025-02-05 23:00:008-KStáhnout
2025-01-27 00:00:008-KStáhnout
2025-01-26 23:00:008-KStáhnout
2024-12-20 00:00:008-KStáhnout
2024-12-19 23:00:008-KStáhnout
2024-11-01 00:00:008-KStáhnout
2024-10-31 23:00:008-KStáhnout
2024-10-30 00:00:008-KStáhnout
2024-10-30 00:00:0010-QStáhnout
2024-10-29 23:00:008-KStáhnout
2024-10-29 23:00:0010-QStáhnout
2024-10-11 01:00:008-KStáhnout
2024-10-11 00:00:008-KStáhnout
2024-08-28 01:00:008-KStáhnout
2024-08-28 00:00:008-KStáhnout
2024-08-01 01:00:008-KStáhnout
2024-08-01 01:00:0010-QStáhnout
2024-08-01 00:00:008-KStáhnout
2024-08-01 00:00:0010-QStáhnout
2024-05-28 01:00:008-KStáhnout
2024-05-28 00:00:008-KStáhnout
2024-05-23 01:00:008-KStáhnout
2024-05-23 00:00:008-KStáhnout
2024-05-01 01:00:008-KStáhnout
2024-05-01 01:00:0010-QStáhnout
2024-05-01 00:00:008-KStáhnout
2024-05-01 00:00:0010-QStáhnout
2024-02-09 00:00:0010-KStáhnout
2024-02-08 23:00:0010-KStáhnout
2024-02-07 00:00:008-KStáhnout
2024-02-06 23:00:008-KStáhnout
2023-11-13 00:00:008-KStáhnout
2023-11-12 23:00:008-KStáhnout
2023-11-09 00:00:008-KStáhnout
2023-11-08 23:00:008-KStáhnout
2023-10-31 00:00:008-KStáhnout
2023-10-31 00:00:0010-QStáhnout
2023-10-30 23:00:008-KStáhnout
2023-10-30 23:00:0010-QStáhnout
2023-10-06 01:00:008-KStáhnout
2023-10-06 00:00:008-KStáhnout
2023-10-05 01:00:008-KStáhnout
2023-10-05 00:00:008-KStáhnout
2023-09-12 01:00:008-KStáhnout
2023-09-12 00:00:008-KStáhnout
2023-08-01 01:00:008-KStáhnout
2023-08-01 01:00:0010-QStáhnout
2023-08-01 00:00:008-KStáhnout
2023-08-01 00:00:0010-QStáhnout
2023-07-13 01:00:008-KStáhnout
2023-07-13 00:00:008-KStáhnout
2023-07-12 01:00:008-KStáhnout
2023-07-12 00:00:008-KStáhnout
2023-05-19 01:00:008-KStáhnout
2023-05-19 00:00:008-KStáhnout
2023-05-03 01:00:008-KStáhnout
2023-05-03 01:00:0010-QStáhnout
2023-05-03 00:00:008-KStáhnout
2023-05-03 00:00:0010-QStáhnout
2023-03-29 01:00:008-KStáhnout
2023-03-29 00:00:008-KStáhnout
2023-02-24 00:00:008-KStáhnout
2023-02-23 23:00:008-KStáhnout
2023-02-10 00:00:008-KStáhnout
2023-02-09 23:00:008-KStáhnout
2023-02-09 00:00:0010-KStáhnout
2023-02-08 23:00:0010-KStáhnout
2023-02-06 00:00:008-KStáhnout
2023-02-05 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-11-01 00:00:008-KStáhnout
2022-11-01 00:00:0010-QStáhnout
2022-10-31 23:00:008-KStáhnout
2022-10-31 23:00:0010-QStáhnout
2022-08-30 01:00:008-KStáhnout
2022-08-30 00:00:008-KStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:008-KStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-06-01 01:00:008-KStáhnout
2022-06-01 00:00:008-KStáhnout
2022-05-25 01:00:008-KStáhnout
2022-05-25 00:00:008-KStáhnout
2022-05-23 01:00:008-KStáhnout
2022-05-23 00:00:008-KStáhnout
2022-05-04 01:00:008-KStáhnout
2022-05-04 01:00:0010-QStáhnout
2022-05-04 00:00:008-KStáhnout
2022-05-04 00:00:0010-QStáhnout
2022-02-11 00:00:008-KStáhnout
2022-02-11 00:00:0010-KStáhnout
2022-02-10 23:00:008-KStáhnout
2022-02-10 23:00:0010-KStáhnout
2022-01-06 00:00:008-KStáhnout
2022-01-05 23:00:008-KStáhnout
2021-12-23 00:00:008-KStáhnout
2021-12-22 23:00:008-KStáhnout
2021-11-22 00:00:008-KStáhnout
2021-11-21 23:00:008-KStáhnout
2021-11-01 00:00:008-KStáhnout
2021-11-01 00:00:0010-QStáhnout
2021-10-31 23:00:008-KStáhnout
2021-10-31 23:00:0010-QStáhnout
2021-08-03 01:00:008-KStáhnout
2021-08-03 01:00:0010-QStáhnout
2021-08-03 00:00:008-KStáhnout
2021-08-03 00:00:0010-QStáhnout
2021-05-21 01:00:008-KStáhnout
2021-05-21 00:00:008-KStáhnout
2021-05-05 01:00:008-KStáhnout
2021-05-05 01:00:0010-QStáhnout
2021-05-05 00:00:008-KStáhnout
2021-05-05 00:00:0010-QStáhnout
2021-04-16 01:00:008-KStáhnout
2021-04-16 00:00:008-KStáhnout
2021-02-05 00:00:0010-KStáhnout
2021-02-04 23:00:0010-KStáhnout
2021-02-04 00:00:008-KStáhnout
2021-02-03 23:00:008-KStáhnout
2021-02-02 00:00:008-KStáhnout
2021-02-01 23:00:008-KStáhnout
2021-01-08 00:00:008-KStáhnout
2021-01-07 23:00:008-KStáhnout
2020-11-24 00:00:008-KStáhnout
2020-11-23 23:00:008-KStáhnout
2020-11-19 00:00:008-KStáhnout
2020-11-18 23:00:008-KStáhnout
2020-11-09 00:00:008-KStáhnout
2020-11-09 00:00:0010-QStáhnout
2020-11-08 23:00:008-KStáhnout
2020-11-08 23:00:0010-QStáhnout
2020-09-10 01:00:008-KStáhnout
2020-09-10 00:00:008-KStáhnout
2020-08-28 01:00:008-KStáhnout
2020-08-28 00:00:008-KStáhnout
2020-08-03 01:00:008-KStáhnout
2020-08-03 01:00:0010-QStáhnout
2020-08-03 00:00:008-KStáhnout
2020-08-03 00:00:0010-QStáhnout
2020-07-28 01:00:008-KStáhnout
2020-07-28 00:00:008-KStáhnout
2020-07-13 01:00:008-KStáhnout
2020-07-13 00:00:008-KStáhnout
2020-06-16 01:00:008-KStáhnout
2020-06-16 00:00:008-KStáhnout
2020-05-21 01:00:008-KStáhnout
2020-05-21 00:00:008-KStáhnout
2020-05-06 01:00:008-KStáhnout
2020-05-06 01:00:0010-QStáhnout
2020-05-06 00:00:008-KStáhnout
2020-05-06 00:00:0010-QStáhnout
2020-04-09 01:00:008-KStáhnout
2020-04-09 00:00:008-KStáhnout
2020-02-07 00:00:0010-KStáhnout
2020-02-06 23:00:0010-KStáhnout
2020-02-05 00:00:008-KStáhnout
2020-02-04 23:00:008-KStáhnout
2020-02-04 00:00:008-KStáhnout
2020-02-03 23:00:008-KStáhnout
2020-01-13 00:00:008-KStáhnout
2020-01-12 23:00:008-KStáhnout
2019-11-04 00:00:008-KStáhnout
2019-11-04 00:00:0010-QStáhnout
2019-11-03 23:00:008-KStáhnout
2019-11-03 23:00:0010-QStáhnout
2019-09-11 01:00:008-KStáhnout
2019-09-11 00:00:008-KStáhnout
2019-07-29 01:00:008-KStáhnout
2019-07-29 01:00:0010-QStáhnout
2019-07-29 00:00:008-KStáhnout
2019-07-29 00:00:0010-QStáhnout
2019-05-23 01:00:008-KStáhnout
2019-05-23 00:00:008-KStáhnout
2019-04-29 01:00:008-KStáhnout
2019-04-29 01:00:0010-QStáhnout
2019-04-29 00:00:008-KStáhnout
2019-04-29 00:00:0010-QStáhnout
2019-04-26 01:00:008-KStáhnout
2019-04-26 00:00:008-KStáhnout
2019-02-08 00:00:0010-KStáhnout
2019-02-07 23:00:0010-KStáhnout
2019-02-05 00:00:008-KStáhnout
2019-02-04 23:00:008-KStáhnout
2019-01-29 00:00:008-KStáhnout
2019-01-28 23:00:008-KStáhnout
2019-01-07 00:00:008-KStáhnout
2019-01-06 23:00:008-KStáhnout
2018-12-12 00:00:008-KStáhnout
2018-12-11 23:00:008-KStáhnout
2018-11-05 00:00:008-KStáhnout
2018-11-05 00:00:0010-QStáhnout
2018-11-04 23:00:008-KStáhnout
2018-11-04 23:00:0010-QStáhnout
2018-09-24 01:00:008-KStáhnout
2018-09-24 00:00:008-KStáhnout
2018-08-03 01:00:008-KStáhnout
2018-08-03 00:00:008-KStáhnout
2018-07-31 01:00:008-KStáhnout
2018-07-31 01:00:0010-QStáhnout
2018-07-31 00:00:008-KStáhnout
2018-07-31 00:00:0010-QStáhnout
2018-07-24 01:00:008-KStáhnout
2018-07-24 00:00:008-KStáhnout
2018-05-30 01:00:008-KStáhnout
2018-05-30 00:00:008-KStáhnout
2018-04-30 01:00:008-KStáhnout
2018-04-30 01:00:0010-QStáhnout
2018-04-30 00:00:008-KStáhnout
2018-04-30 00:00:0010-QStáhnout
2018-02-14 00:00:008-KStáhnout
2018-02-13 23:00:008-KStáhnout
2018-02-13 00:00:008-KStáhnout
2018-02-13 00:00:0010-KStáhnout
2018-02-12 23:00:008-KStáhnout
2018-02-12 23:00:0010-KStáhnout
2018-02-09 00:00:008-KStáhnout
2018-02-08 23:00:008-KStáhnout
2018-01-08 00:00:008-KStáhnout
2018-01-07 23:00:008-KStáhnout
2017-12-05 00:00:008-KStáhnout
2017-12-04 23:00:008-KStáhnout
2017-11-01 00:00:008-KStáhnout
2017-11-01 00:00:0010-QStáhnout
2017-10-31 23:00:008-KStáhnout
2017-10-31 23:00:0010-QStáhnout
2017-10-19 01:00:008-KStáhnout
2017-10-19 00:00:008-KStáhnout
2017-10-17 01:00:008-KStáhnout
2017-10-17 00:00:008-KStáhnout
2017-10-10 01:00:008-KStáhnout
2017-10-10 00:00:008-KStáhnout
2017-10-05 01:00:008-KStáhnout
2017-10-05 00:00:008-KStáhnout
2017-08-03 01:00:008-KStáhnout
2017-08-03 01:00:0010-QStáhnout
2017-08-03 00:00:008-KStáhnout
2017-08-03 00:00:0010-QStáhnout
2017-07-12 01:00:008-KStáhnout
2017-07-12 00:00:008-KStáhnout
2017-07-05 01:00:008-KStáhnout
2017-07-05 00:00:008-KStáhnout
2017-06-09 01:00:008-KStáhnout
2017-06-09 00:00:008-KStáhnout
2017-05-24 01:00:008-KStáhnout
2017-05-24 00:00:008-KStáhnout
2017-05-09 01:00:008-KStáhnout
2017-05-09 01:00:0010-QStáhnout
2017-05-09 00:00:008-KStáhnout
2017-05-09 00:00:0010-QStáhnout
2017-05-02 01:00:008-KStáhnout
2017-05-02 00:00:008-KStáhnout
2017-04-25 01:00:008-KStáhnout
2017-04-25 00:00:008-KStáhnout
2017-04-12 01:00:008-KStáhnout
2017-04-12 00:00:008-KStáhnout
2017-03-13 00:00:008-KStáhnout
2017-03-12 23:00:008-KStáhnout
2017-02-14 00:00:008-KStáhnout
2017-02-14 00:00:0010-KStáhnout
2017-02-13 23:00:008-KStáhnout
2017-02-13 23:00:0010-KStáhnout
2017-02-10 00:00:008-KStáhnout
2017-02-09 23:00:008-KStáhnout
2017-01-06 00:00:008-KStáhnout
2017-01-05 23:00:008-KStáhnout
2016-12-23 00:00:008-KStáhnout
2016-12-22 23:00:008-KStáhnout
2016-11-02 00:00:008-KStáhnout
2016-11-02 00:00:0010-QStáhnout
2016-11-01 23:00:008-KStáhnout
2016-11-01 23:00:0010-QStáhnout
2016-10-11 01:00:008-KStáhnout
2016-10-11 00:00:008-KStáhnout
2016-09-23 01:00:008-KStáhnout
2016-09-23 00:00:008-KStáhnout
2016-08-03 01:00:008-KStáhnout
2016-08-03 01:00:0010-QStáhnout
2016-08-03 00:00:008-KStáhnout
2016-08-03 00:00:0010-QStáhnout
2016-05-24 01:00:008-KStáhnout
2016-05-24 00:00:008-KStáhnout
2016-05-05 01:00:008-KStáhnout
2016-05-05 01:00:0010-QStáhnout
2016-05-05 00:00:008-KStáhnout
2016-05-05 00:00:0010-QStáhnout
2016-02-11 00:00:008-KStáhnout
2016-02-11 00:00:0010-KStáhnout
2016-02-10 23:00:008-KStáhnout
2016-02-10 23:00:0010-KStáhnout
2016-02-05 00:00:008-KStáhnout
2016-02-04 23:00:008-KStáhnout
2015-12-02 00:00:008-KStáhnout
2015-12-01 23:00:008-KStáhnout
2015-10-29 00:00:008-KStáhnout
2015-10-29 00:00:0010-QStáhnout
2015-10-28 23:00:008-KStáhnout
2015-10-28 23:00:0010-QStáhnout
2015-10-08 01:00:008-KStáhnout
2015-10-08 00:00:008-KStáhnout
2015-10-02 01:00:008-KStáhnout
2015-10-02 00:00:008-KStáhnout
2015-09-04 01:00:008-KStáhnout
2015-09-04 00:00:008-KStáhnout
2015-07-29 01:00:008-KStáhnout
2015-07-29 01:00:0010-QStáhnout
2015-07-29 00:00:008-KStáhnout
2015-07-29 00:00:0010-QStáhnout
2015-06-01 01:00:008-KStáhnout
2015-06-01 00:00:008-KStáhnout
2015-04-30 01:00:008-KStáhnout
2015-04-30 01:00:0010-QStáhnout
2015-04-30 00:00:008-KStáhnout
2015-04-30 00:00:0010-QStáhnout
2015-04-01 01:00:008-KStáhnout
2015-04-01 00:00:008-KStáhnout
2015-02-19 00:00:008-KStáhnout
2015-02-18 23:00:008-KStáhnout
2015-02-09 00:00:008-KStáhnout
2015-02-09 00:00:0010-KStáhnout
2015-02-08 23:00:008-KStáhnout
2015-02-08 23:00:0010-KStáhnout
2015-02-05 00:00:008-KStáhnout
2015-02-04 23:00:008-KStáhnout
2014-11-04 00:00:0010-QStáhnout
2014-11-03 23:00:0010-QStáhnout
2014-11-03 00:00:008-KStáhnout
2014-11-02 23:00:008-KStáhnout
2014-08-06 01:00:008-KStáhnout
2014-08-06 01:00:0010-QStáhnout
2014-08-06 00:00:008-KStáhnout
2014-05-22 01:00:008-KStáhnout
2014-05-22 00:00:008-KStáhnout
2014-05-01 01:00:0010-QStáhnout
2014-05-01 00:00:0010-QStáhnout
2014-04-30 01:00:008-KStáhnout
2014-04-30 00:00:008-KStáhnout
2014-02-27 00:00:008-KStáhnout
2014-02-26 23:00:008-KStáhnout
2014-02-25 00:00:008-KStáhnout
2014-02-24 23:00:008-KStáhnout
2014-02-11 00:00:0010-KStáhnout
2014-02-10 23:00:0010-KStáhnout
2014-02-06 00:00:008-KStáhnout
2014-02-05 23:00:008-KStáhnout
2014-01-20 23:00:008-KStáhnout
2013-10-28 23:00:0010-QStáhnout
2013-07-26 00:00:0010-QStáhnout
2013-07-25 00:00:008-KStáhnout
2013-05-28 00:00:008-KStáhnout
preloader